Sanofi Reports P-IIb Study (STREAM-AD) Results of Amlitelimab for the Treatment of Atopic Dermatitis
Shots:
- The P-IIb study evaluating amlitelimab, a fully human non-depleting mAb that binds to OX40-Ligand vs PBO in 390 adult patients across Australia, Bulgaria, Canada, Czechia, Germany, Hungary, Japan, Poland, Spain, Taiwan, the UK & the US
- The trial met its 1EPs & showed an improvement in avg. EASI score from baseline at 16wks. for all 4 subcutaneous doses, improvements + also seen in 2EPs at 16 & 24wks. with continued improvement through 24wks. in primary & secondary outcomes while biomarker results support an effect on type 2 & non-type 2 pathways
- The therapy was well-tolerated across all dose arms with no new safety concerns. Amlitelimab is designed to restore immune homeostasis b/w pro-inflammatory & regulatory T cells by targeting the OX40-ligand
Ref: Sanofi | Image: Sanofi
Related News:- Sanofi Presents Results of Amlitelimab (KY1005) in P-IIa Study for the Treatment of Moderate-To-Severe Atopic Dermatitis at EADV 2021
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
